Next Article in Journal
The Role of RNA Interference (RNAi) in Arbovirus-Vector Interactions
Previous Article in Journal
Bioinformatics Tools for Small Genomes, Such as Hepatitis B Virus
Article Menu

Export Article

Open AccessArticle
Viruses 2015, 7(2), 798-819; doi:10.3390/v7020798

Intranasal Administration of Maleic Anhydride-Modified Human Serum Albumin for Pre-Exposure Prophylaxis of Respiratory Syncytial Virus Infection

1
Key Lab of Medical Molecular Virology of MOE/MOH, Shanghai Medical College, Fudan University, 130 Dong An Rd., Xuhui District, Shanghai 200032, China
2
Laboratory Medicine Center, Pediatric Institute, Children's Hospital of Fudan University, 399 Wanyuan Road, Shanghai, 201102, China
3
Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA
*
Authors to whom correspondence should be addressed.
Academic Editor: Curt Hagedorn
Received: 16 October 2014 / Revised: 5 February 2015 / Accepted: 10 February 2015 / Published: 16 February 2015
View Full-Text   |   Download PDF [1382 KB, uploaded 12 May 2015]   |  

Abstract

Respiratory syncytial virus (RSV) is the leading cause of pediatric viral respiratory tract infections. Neither vaccine nor effective antiviral therapy is available to prevent and treat RSV infection. Palivizumab, a humanized monoclonal antibody, is the only product approved to prevent serious RSV infection, but its high cost is prohibitive in low-income countries. Here, we aimed to identify an effective, safe, and affordable antiviral agent for pre-exposure prophylaxis (PrEP) of RSV infection in children at high risk. We found that maleic anhydride (ML)-modified human serum albumin (HSA), designated ML-HSA, exhibited potent antiviral activity against RSV and that the percentages of the modified lysines and arginies in ML- are correlated with such anti-RSV activity. ML-HSA inhibited RSV entry and replication by interacting with viral G protein and blocking RSV attachment to the target cells, while ML-HAS neither bound to F protein, nor inhibited F protein-mediated membrane fusion. Intranasal administration of ML-HSA before RSV infection resulted in significant decrease of the viral titers in the lungs of mice. ML-HSA shows promise for further development into an effective, safe, affordable, and easy-to-use intranasal regimen for pre-exposure prophylaxis of RSV infection in children at high risk in both low- and high-income countries. View Full-Text
Keywords: human serum albumin (HSA); pre-exposure prophylaxis (PrEP); respiratory syncytial virus (RSV); entry inhibitor; antiviral human serum albumin (HSA); pre-exposure prophylaxis (PrEP); respiratory syncytial virus (RSV); entry inhibitor; antiviral
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Sun, Z.; Wang, Q.; Jia, R.; Xia, S.; Li, Y.; Liu, Q.; Xu, W.; Xu, J.; Du, L.; Lu, L.; Jiang, S. Intranasal Administration of Maleic Anhydride-Modified Human Serum Albumin for Pre-Exposure Prophylaxis of Respiratory Syncytial Virus Infection. Viruses 2015, 7, 798-819.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top